Siren, L.L.C. Allovir, Inc. Call Options Transaction History
Siren, L.L.C.
- $2.26 Trillion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALVR
# of Institutions
49Shares Held
21.1MCall Options Held
41KPut Options Held
100-
Israel Englander Millennium Management LLC | New York, Ny3.03MShares$28.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$25.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.91MShares$18.1 Million0.06% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ664KShares$6.32 Million0.0% of portfolio
-
Black Rock Inc. New York, NY634KShares$6.03 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $885M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...